Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Revenue of Geron Corporation (GERN)
Revenue in 2023 (TTM): $237 K
According to Geron Corporation's latest financial reports the company's current revenue (TTM) is $237 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Geron Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $237 K | $-795,999 | $-192,911,000 | $-184,127,000 | $-184,127,000 |
| 2022 | $596 K | $-272,000 | $-135,019,000 | $-141,901,000 | $-141,033,000 |
| 2021 | $1.39 M | $610 K | $-111,589,000 | $-116,112,000 | $-120,952,000 |
| 2020 | $253 K | $-49,799,000 | $-74,917,000 | $-75,617,000 | $-75,610,000 |
| 2019 | $460 K | $-50,812,000 | $-72,505,000 | $-68,548,000 | $-63,551,000 |
| 2018 | $1.07 M | $-11,657,000 | $-32,533,000 | $-27,017,000 | $-27,017,000 |
| 2017 | $1.07 M | $-7,372,000 | $-27,839,000 | $-27,916,000 | $-27,916,000 |
| 2016 | $6.16 M | $-8,533,000 | $-29,454,000 | $-29,537,000 | $-29,537,000 |
| 2015 | $36.37 M | $26.8 M | $1.42 M | $46 K | $46 K |
| 2014 | $1.15 M | $-7,748,000 | $-35,939,000 | $-35,670,000 | $-35,670,000 |
| 2013 | $1.28 M | $-7,851,000 | $-36,225,000 | $-38,379,000 | $-38,379,000 |
| 2012 | $2.71 M | $-22,469,000 | $-65,959,000 | $-68,881,000 | $-68,881,000 |
| 2011 | $2.44 M | $2.44 M | $-82,617,000 | $-96,853,000 | $-96,853,000 |
| 2010 | $3.56 M | $3.56 M | $-41,357,000 | $-111,377,000 | $-111,377,000 |
| 2009 | $1.73 M | $1.73 M | $-70,391,000 | $-70,184,000 | $-70,184,000 |
| 2008 | $2.8 M | $2.8 M | $-65,040,000 | $-62,021,000 | $-62,021,000 |
| 2007 | $7.62 M | $7.62 M | $-76,362,000 | $-36,697,000 | $-36,697,000 |
| 2006 | $3.28 M | $3.28 M | $-53,192,000 | $-31,365,000 | $-31,365,000 |
| 2005 | $290 K | $290 K | $-39,835,000 | $-33,528,000 | $-33,528,000 |
| 2004 | $1.05 M | $1.05 M | $12.92 M | $-80,405,000 | $-80,405,000 |
| 2003 | $1.17 M | $1.17 M | $-25,279,000 | $-29,883,000 | $-29,883,000 |
| 2002 | $1.25 M | $1.25 M | $-31,110,000 | $ | $-33,908,000 |
| 2001 | $3.62 M | $3.62 M | $-18,739,000 | $-46,929,000 | $-42,073,000 |
| 2000 | $6.61 M | $11.26 M | $-21,559,000 | $ | $-45,833,000 |
| 1999 | $5.4 M | $9.1 M | $6.3 M | $-44,200,000 | $-46,400,000 |
| 1998 | $6.8 M | $8.5 M | $-13,600,000 | $-9,900,000 | $-10,800,000 |
| 1997 | $7.3 M | $8.9 M | $-11,100,000 | $-9,100,000 | $-9,600,000 |
| 1996 | $5.3 M | $6.5 M | $-12,800,000 | $-10,400,000 | $-10,700,000 |